Clinical Trial Update: CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial evaluating a dual-target CAR-T therapy (CAR19-BCMA) for relapsed/refractory multiple myeloma is currently recruiting in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CAR19-BCMA Dual-target CAR-T

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Multiple Myeloma | EARLY_Phase 1 | Status: RECRUITING